TickerFacts.

A business in context

ATYR research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-09-07 · 8010 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001339970-26-000053

  2. 8-K · Current report

    Report date 2026-08-07 · 0001339970-26-000051 · Items 2.02,9.01

  3. 8-K · Current report

    Report date 2026-07-30 · 0001339970-26-000042 · Items 1.02,9.01

  4. 8-K · Current report

    Report date 2026-06-03 · 0001339970-26-000039 · Items 3.01

  5. 8-K · Current report

    Report date 2026-06-01 · 0001339970-26-000036 · Items 7.01,9.01

  6. 4 · Ownership change

    Report date 2026-05-27 · 0001236447-26-000006

  7. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001339970-26-000033

  8. 8-K · Current report

    Report date 2026-05-15 · 0001339970-26-000030 · Items 2.02,9.01

  9. 4 · Ownership change

    Report date 2026-05-11 · 0001781292-26-000003

  10. 4 · Ownership change

    Report date 2026-05-11 · 0001684258-26-000003

  11. 4 · Ownership change

    Report date 2026-05-11 · 0001643653-26-000014

  12. 4 · Ownership change

    Report date 2026-05-11 · 0001602225-26-000003

  13. 4 · Ownership change

    Report date 2026-05-11 · 0001376043-26-000003

  14. 4 · Ownership change

    Report date 2026-05-11 · 0001236447-26-000003

  15. 8-K · Current report

    Report date 2026-05-11 · 0001339970-26-000027 · Items 2.02,7.01,8.01,9.01

  16. DEF 14A · Proxy statement

    Report date 2026-03-26 · 0001339970-26-000021

  17. 10-K · Annual report

    Report date 2025-12-31 · 0001339970-26-000008

  18. 8-K · Current report

    Report date 2026-03-05 · 0001339970-26-000006 · Items 2.02,9.01

  19. 4 · Ownership change

    Report date 2026-02-03 · 0001193125-26-038007

  20. 8-K · Current report

    Report date 2025-12-04 · 0001193125-25-309619 · Items 3.01

  21. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-269587

  22. 8-K · Current report

    Report date 2025-11-06 · 0001193125-25-269486 · Items 2.02,9.01

  23. 8-K · Current report

    Report date 2025-09-15 · 0001193125-25-202865 · Items 8.01,9.01

  24. 8-K/A · Current report

    Report date 2025-08-07 · 0001339970-25-000016 · Items 2.02,9.01

  25. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001339970-25-000009

  26. 8-K · Current report

    Report date 2025-08-07 · 0001339970-25-000007 · Items 2.06,9.01

  27. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-065640

  28. 8-K · Current report

    Report date 2025-05-07 · 0000950170-25-065611 · Items 2.02,9.01

  29. 8-K · Current report

    Report date 2025-05-01 · 0000950170-25-064413 · Items 5.02,5.07,9.01

  30. DEF 14A · Proxy statement

    Report date 2025-03-19 · 0000950170-25-041992

  31. 10-K · Annual report

    Report date 2024-12-31 · 0000950170-25-038888

  32. 8-K · Current report

    Report date 2025-03-13 · 0000950170-25-038703 · Items 2.02,9.01

  33. 8-K · Current report

    Report date 2024-12-23 · 0000950170-24-139633 · Items 1.01,9.01

  34. 8-K · Current report

    Report date 2024-12-10 · 0000950170-24-135766 · Items 5.02,9.01

  35. SC 13G/A · Ownership disclosure

    0000935836-24-000727

  36. 10-Q · Quarterly report

    Report date 2024-09-30 · 0000950170-24-123305

  37. 8-K · Current report

    Report date 2024-11-07 · 0000950170-24-123256 · Items 2.02,9.01

  38. SC 13G · Ownership disclosure

    0000902664-24-005837

  39. SC 13G/A · Ownership disclosure

    0001623632-24-001769

  40. 10-Q · Quarterly report

    Report date 2024-06-30 · 0000950170-24-096185

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 1 transaction rows1PSale: 0 transaction rows0SGrant / award: 6 transaction rows6AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

7 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-05-27
2026-05-28
SCHIMMEL PAULP · Purchase
Acquired
Common Stock100000.00.5
2026-05-11
2026-05-13
Lucas SvetlanaA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
50000.00.0
2026-05-11
2026-05-13
Gross Jane AA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
50000.00.0
2026-05-11
2026-05-13
BENEVICH ERICA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
50000.00.0
2026-05-11
2026-05-13
Zaknoen SaraA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
50000.00.0
2026-05-11
2026-05-13
Coughlin TimothyA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
50000.00.0
2026-05-11
2026-05-13
SCHIMMEL PAULA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
50000.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001339970aTYR PHARMA INC

No parent relationship is available in this import; this is not proof of independence.

Legal Entity Identifier
529900ENQUXMC5EBKO36
GLEIF legal name
Atyr Pharma, Inc.
Entity / LEI registration status
ACTIVE / LAPSED
Reference data updated
2021-07-15T05:09:24Z

direct-parent: no parent LEI supplied

ultimate-parent: no parent LEI supplied

GLEIF legal entity reference data · retrieved 2026-09-07 · 1177 checked identities; 0 unavailable records

Search names and former names

View Wikidata identity and references ↗

  • aTyr Pharma · alias · wikidata
Explore headquarters map ↗

Revenue in constant purchasing power

USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$235.0K$250.1K
2023-12-31$353.0K$386.8K
2022-12-31$10.39M$11.85M
2021-12-31$0$0
2020-12-31$10.46M$13.49M
2019-12-31$422.0K$551.1K

Bureau of Labor Statistics · retrieved 2026-09-07 · 9 selected series; gaps remain missing

Explore the CPI history ↗